Plain-English translation of NCT06783790 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of three medications—avapritinib, azacitidine, and venetoclax—can help patients whose acute myeloid leukemia (a serious blood cancer) has returned after they received a stem cell transplant. The study wants to see if this treatment combination is safe and effective for people with specific genetic changes in their cancer cells. About 20 patients will participate.
When acute myeloid leukemia comes back after a stem cell transplant, treatment options are limited and outcomes are often poor. This trial is testing whether a new combination of medications might offer hope to these patients by targeting the specific genetic mutations that are driving their cancer.
You likely qualify if…
You likely don't qualify if…
You would take the three medications by mouth for the first phase of treatment lasting 28 days. After each 28-day cycle, your doctors would check how well the treatment is working using blood tests and bone marrow samples. If your cancer goes into remission (improves significantly), you would move to a second phase where you take one of the medications alone for four more cycles of 28 days each. Throughout the study, you would have regular clinic visits for blood work, checkups, and monitoring to make sure the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Enrollment target
~20 participants
Started
January 2025
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Erlie Jiang
Institute of Hematology & Blood Diseases Hospital, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.